Celgene Corp. (CELG) Stock Rating Reaffirmed by RBC Capital Markets
's stock had its "outperform" rating restated by investment analysts at RBC Capital Markets in a research report issued to clients and investors on Sunday. Other analysts have also issued reports about the company.
from Biotech News
0 Comments